330 related articles for article (PubMed ID: 30635338)
1. Vaccine-Induced Memory CD8
Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
[TBL] [Abstract][Full Text] [Related]
2. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
3. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
Gall VA; Philips AV; Qiao N; Clise-Dwyer K; Perakis AA; Zhang M; Clifton GT; Sukhumalchandra P; Ma Q; Reddy SM; Yu D; Molldrem JJ; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res; 2017 Oct; 77(19):5374-5383. PubMed ID: 28819024
[TBL] [Abstract][Full Text] [Related]
7. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
8. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.
Moran TP; Burgents JE; Long B; Ferrer I; Jaffee EM; Tisch RM; Johnston RE; Serody JS
Vaccine; 2007 Sep; 25(36):6604-12. PubMed ID: 17675184
[TBL] [Abstract][Full Text] [Related]
9. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
[TBL] [Abstract][Full Text] [Related]
10. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
[TBL] [Abstract][Full Text] [Related]
11. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245
[TBL] [Abstract][Full Text] [Related]
13. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
[TBL] [Abstract][Full Text] [Related]
14. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.
Wang X; Wang JP; Maughan MF; Lachman LB
Breast Cancer Res; 2005; 7(1):R145-55. PubMed ID: 15642163
[TBL] [Abstract][Full Text] [Related]
15. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
16. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
17. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients.
Occhipinti S; Sponton L; Rolla S; Caorsi C; Novarino A; Donadio M; Bustreo S; Satolli MA; Pecchioni C; Marchini C; Amici A; Cavallo F; Cappello P; Pierobon D; Novelli F; Giovarelli M
Clin Cancer Res; 2014 Jun; 20(11):2910-21. PubMed ID: 24668647
[TBL] [Abstract][Full Text] [Related]
18. HER2 dendritic cell vaccines.
Morse MA; Clay TM; Colling K; Hobeika A; Grabstein K; Cheever MA; Lyerly HK
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S164-72. PubMed ID: 12620155
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic Activity and Memory T Cell Subset Distribution of
Kuznetsova M; Lopatnikova J; Shevchenko J; Silkov A; Maksyutov A; Sennikov S
Front Immunol; 2019; 10():1017. PubMed ID: 31143180
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.
Crosby EJ; Hobeika AC; Niedzwiecki D; Rushing C; Hsu D; Berglund P; Smith J; Osada T; Gwin Iii WR; Hartman ZC; Morse MA; Lyerly HK
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
